The purpose of this study is 1) to evaluate the feasibility of manufacturing a patient-specific neoantigen cancer vaccine, which involves predicting the patient's neoantigens and generating a vaccine that encodes the predicted neoantigens; and, 2) to identify and select patients who may be eligible for a shared neoantigen cancer vaccine where their tumor contains a specific shared mutation and who have the correct HLA allele capable of presenting the neoantigen derived from the tumor-specific mutation.

Gritstone is developing two neoantigen-based cancer vaccines: the first is a patient-specific cancer vaccine that requires a manufacturing period for each patient and the second is an off-the-shelf cancer vaccine that targets shared neoantigens.

The process of generating a patient-specific neoantigen cancer vaccine involves multiple steps, including collection of patient tumor and blood specimens, performing next-generation sequencing (NGS), predicting the neoantigens to be included in the patient-specific vaccine, and the manufacture and release of the patient-specific vaccine. Gaining experience in managing the manufacturing process will provide important insights and experience regarding this process to be used in operationalizing future clinical trials.

Selecting patients who may be eligible to receive a shared neoantigen vaccine requires first identifying patients whose tumor possesses a neoantigen derived from an oncogenic mutation that is encoded by the vaccine, and then determining whether the patient expresses a matching HLA allele for antigen presentation.

Study participants will not receive any investigational treatment as part of this trial. Patients screened in this study may be able to enroll in a separate investigational treatment study sponsored by Gritstone Oncology, provided that the patient meets the specified eligibility criteria for that treatment study.

Group 1 Inclusion Criteria:

• Provide a signed and dated informed consent form prior to initiation of study-specific procedures

• Patients with the indicated advanced or metastatic solid tumor as follows:

  1. NSCLC who have received ≤ 1 cycle of systemic treatment with cytotoxic, platinum-based chemotherapy (Note: patients with NSCLC who are receiving pembrolizumab monotherapy as first line systemic monotherapy are eligible)
  2. GEA who have received ≤ 1 cycle of systemic treatment with cytotoxic, platinum-based chemotherapy
  3. mUC who have received ≤ 1 cycle of systemic treatment with cytotoxic, platinum-based chemotherapy
  4. CRC-microsatellite stable (MSS) who have received ≤ 1 cycle of second line systemic therapy including a fluoropyrimidine and oxaliplatin or irinotecan (Note: patients receiving first-line systemic therapy are eligible)

• 18 years of age or older

• ECOG Performance Status 0 or 1

• Available FFPE tumor specimen for sequencing and neoantigen selection

• Measurable disease according to RECIST v1.1 Have adequate organ function, as measured by laboratory values (criteria listed in protocol)

Group 1 Exclusion Criteria:

• Tumors with genetic characteristics as follows:

  1. For NSCLC, patients with a known driver genomic alteration in EGFR, ALK, ROS1, RET, or TRK
  2. For CRC or GEA, patients with MSI disease
  3. For CRC, patients with a known BRAF mutation or patients with peritoneal carcinomatosis

Group 2 Inclusion Criteria:

• Provide a signed and dated informed consent form prior to initiation of study-specific procedures

• Patient's tumor possesses one of the mutations listed in the clinical study protocol, as determined per local institutional standard

• Patients with an advanced or metastatic solid tumor as follows:

  1. MSS-CRC who are currently receiving systemic treatment with a fluoropyrimidine and oxaliplatin or irinotecan that may include a VEGF or EGFR targeting therapy as their first-line or second-line therapy for metastatic disease
  2. NSCLC who are currently receiving systemic treatment with cytotoxic, platinum-based chemotherapy in combination with an anti-PD-(L)1 antibody
  3. PDA who are currently receiving systemic cytotoxic chemotherapy as their first-line therapy for metastatic disease

Group 2 Exclusion Criteria

• Patients with MSI disease
• Patients with NSCLC with a known driver genomic alteration in EGFR, ALK, ROS1, RET, or TRK

Complete inclusion and exclusion criteria are listed in the clinical study protocol.

Oncology